Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich.
We analyzed characteristics, therapy and outcome of patients with bilateral testicular germ cell tumor (TGCT) at our institutions. Among 1,180 TGCT patients diagnosed and/or treated between 1979 and 2003, 47 (4.0%) developed a second TGCT. Nine of 14 patients (64%) with synchronous TGCT are alive with no evidence of disease (NED) at a median follow-up of 37 months. Thirty-three patients had a metachronous bilateral TGCT. Median time to the 2(nd) TGCT was 71 months. At diagnosis of 2(nd) TGCT 30 patients had stage I, 1 had stage II and 2 had stage III disease. Thirty-two of 33 patients are alive with NED at a median follow up of 41 months. No patient died from second TGCT. As a review of the literature confirms our data we do not recommend a routine biopsy of the contralateral testicle for early detection of testicular intraepithelial neoplasia (TIN).
Hentrich
Marcus
M
Department of Medical Oncology, Munich Harlaching Hospital, Sanatoriumsplatz 2, 81545, Munich, Germany. tumorzentrum.hentrich@khmh.de
Weber
Norbert
N
Bergsdorf
Thorsten
T
Liedl
Bernhard
B
Hartenstein
Reiner
R
Gerl
Arthur
A
D000293:Adolescent; D000328:Adult; D001706:Biopsy; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000473:pathology / Q000628:therapy*; D009378:Neoplasms, Multiple Primary / Q000473:pathology / Q000628:therapy*; D016609:Neoplasms, Second Primary / Q000473:pathology / Q000628:therapy*; D009919:Orchiectomy; D011379:Prognosis; D018239:Seminoma / Q000473:pathology / Q000628:therapy; D013736:Testicular Neoplasms / Q000473:pathology / Q000628:therapy*; D013737:Testis / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome